Related Experiment Video
Updated: Jun 23, 2025

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
Published on: April 28, 2016
Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions
1Department of Obesity and Nutritional Sciences, Novo Nordisk Foundation, Hellerup, Denmark. ara@novo.dk.
Abstract:
Scientists were chasing an incretin hormone, and when GLP-1 was finally discovered, we found that it had a pronounced satiety effect, slowed down gastric emptying, and actually reduced postprandial insulin response. These mechanisms are the basis for the highly efficacious GLP-1 analogues that today offer safe and effective treatment in millions of people living with obesity. Moreover, the combined GLP-1 mechanisms of weight loss and delayed carbohydrate absorption may also be the key drivers of remission of type 2 diabetes and reduced cardiovascular events found by GLP-1 analogues.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Regulation of Food Intake
Hormonal Regulation
Dipeptidyl Peptidase 4 Inhibitors
GPCRs Regulate Adenylyl Cylase Activity
Obesity

